
    
      There is an increased awareness that the bacteria which forms our microbiome, plays a crucial
      role in human health and diseases. Numerous studies have highlighted the therapeutic
      potential of specific bacteria in preventing and treating metabolic, gastrointestinal and
      other diseases.

      The aim of the study is evaluate the effect of administration of a next generation probiotic,
      Eubacterium hallii, versus placebo on insulin sensitivity and glycemic control, in volunteers
      with some markers of metabolic syndrome.

      Participants will receive their randomized study product daily for 12 weeks. The target
      population will be otherwise healthy hyperglycaemic males.
    
  